Alzheimer's and type 2 diabetes treatment via common enzyme targeting

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 2, 2014, Pages 299-304

  Jabir, Nasimudeen R ^a   Kamal, Mohammad A ^a   Abuzenadah, Adel Mohammad ^a   Gan, Siew Hua ^b   Alama, Mohammed Nabil ^c   Baeesa, Saleh S ^a   Tabrez, Shams ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^c KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

Author keywords

Alzheimer's disease; Diabetes; Drug therapy; Endocrine disorders; Enzymes

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; BETA SECRETASE 1; BETA SECRETASE INHIBITOR; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CT 20026; CT 99021; DONEPEZIL; ESOLERINE; GALANGIN; GALANTAMINE; GLUCAGON LIKE PEPTIDE 1; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HUPERZINE A; HUPERZINE B; INSULIN; INSULINASE; LADOSTIGIL; LY2811376; MK8931; PHENSERINE; RG7129; RIVASTIGMINE; STRESS ACTIVATED PROTEIN KINASE; TACRINE; TIDEGLUSIB; TOLSERINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ENZYME INHIBITOR;

ALZHEIMER DISEASE; BIOLOGICAL THERAPY; CHOLESTEROL METABOLISM; CHOLINERGIC TRANSMISSION; ENZYME INHIBITION; ENZYME TARGETED THERAPY; HUMAN; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; ANIMAL; DIABETES MELLITUS, TYPE 2; ENZYMOLOGY;

ALZHEIMER DISEASE; ANIMALS; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; HUMANS;

EID: 84904471060     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113126660145     Document Type: Review

References (84)

1. Yu QS, Reale M, Kamal MA, et al. Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1: N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-synuclein synthesis, interleukin-1β release and cholinergic action. Anti-inflammatory & anti-allergy agents in medicinal chemistry: 2013; 12(2): 117-28.
2. Hampel H, Prvulovic D, Teipel S, et al. The future of Alzheimer's disease: the next 10 years. Prog Neurobiol 2011; 95(4): 718-28.
3. Batsch N, Mittelman M. Overcoming the stigma of dementia; Alzheimer's Disease International: London, 2012.
4. Akter K, Lanza EA, Martin SA, et al. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol 2011; 71(3): 365-76.
5. Götz J, Ittner, LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci 2008; 9(7): 532-44.
6. Winblad B, Jelic, V. Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis Assoc Disord 2004; 18 Suppl 1: S2-8.
7. Götz J, Ittner L, Lim, Y. Common features between diabetes mellitus and Alzheimer's disease. Cell Mol Life Sci 2009; 66(8): 1321-5.
8. Harrison LC, Honeyman MC, Steele CE, et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004; 27(10): 2348-55.
9. Priyadarshini M, Kamal MA, Greig NH, et al. Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase. CNS Neurol Disord Drug Targets 2012; 11(4): 482-9.
10. Park S. A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J Clin Neurol 2011; 7(1): 10-18.
11. Li L, Hölscher C. Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 2007; 56(2): 384-402.
12. Exalto L, Whitmer R, Kappele L, Biessels, G. An update on type 2 diabetes, vascular dementia and Alzheimer's disease. Exp Gerontol 2012; 47(11): 858-64.
13. Sridhar GR, Thota H, Allam AR, et al. Alzheimer's disease and type 2 diabetes mellitus: the cholinesterase connection? Lipids Health Dis 2006; 5: 28.
14. Biessels GJ, Kappelle LJ. Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans 2005; 33(Pt 5): 1041-4.
15. Kamal MA, Tan Y, Seale JP, Qu, X. Targeting BuChE-inflammatory pathway by SK0506 to manage type 2 diabetes and Alzheimer disease. Neurochem Res 2009; 34(12): 2163-9.
16. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in lateonset confirmed Alzheimer's disease. Hum Mol Genet 1997; 6(11): 1933-6.
17. Mattila KM, Rinne JO, Röyttä M, et al. Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology. J Med Genet 2000; 37(10): 766-70.
18. Raygani AV, Zahrai M, Soltanzadeh A, et al. Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease. Neurosci Lett 2004; 371(2-3): 142-6.
19. Banu S, Jabir NR, Manjunath CN, Shakil S, Kamal, MA. C-peptide and its correlation to parameters of insulin resistance in the metabolic syndrome. CNS Neurol Disord Drug Targets 2011; 10(8): 921-7.
20. de la Monte SM, Wands, JR. Review of insulin and insulin-like growth factor expression, signaling and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis 2005; 7(1): 45-61.
21. Morris JK, Burns, JM. Insulin: an emerging treatment for Alzheimer's disease dementia? Curr Neurol Neurosci Rep 2012; 12(5): 520-7.
22. Reddy V, Zhu X, Perry G, Smith M. Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis 2009; 16(4): 763-74.
23. Mao P. Oxidative Stress and Its Clinical Applications in Dementia. J Neurodegener Dis 2013; 2013: 1-15.
24. Takeuchi M, Yamagishi SI. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr Pharm Des 2008; 14(10): 973-8.
25. Sasaki N, Toki S, Chowei H, et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 2001; 888(2): 256-62.
26. Lue L, Andrade C, Sabbagh M, Walker D. Is There Inflammatory Synergy in Type II DiabetesMellitus and Alzheimer's Disease? Int J Alzheimers Dis 2012; 2012: 918680.
27. Kang J, Rivest S. Lipid metabolism and neuroinflammation in Alzheimer's disease: a role for liver x receptors. Endocr Rev 2012; 33(5): 715-46.
28. Singh-Manoux A, Czernichow S, Elbaz A, et al. Obesity phenotypes in midlife and cognition in early old age: the Whitehall II cohort study. Neurology 2012; 79(8): 755-62.
29. Brown BM, Peiffer JJ, Taddei K, et al. Physical activity and amyloid-β plasma and brain levels: results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. Mol Psychiatry 2013; 18(8): 875-81.
30. Vepsäläinen S, Parkinson M, Helisalmi S, et al. Insulin-degrading enzyme is genetically associated with Alzheimer's disease in the Finnish population. J Med Genet 2007; 44(9): 606-8.
31. Al-Jafari AA, Shakil S, Reale M, Kamal, MA. Human platelet acetylcholinesterase inhibition by cyclophosphamide: a combined experimental and computational approach. CNS Neurol Disord Drug Targets 2011; 10(8): 928-35.
32. Kamal MA, Klein P, Luo W, et al. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine. Neurochem Res 2008; 33(5): 745-53.
33. Kamal MA, Klein P, Yu QS, et al. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. J Alzheimers Dis 2006; 10(1): 43-51.
34. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensinconverting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensinaldosterone system inhibitors involving 158:998 patients. Eur Heart J 2012; 33(16): 2088-97.
35. Leissring MA, Malito E, Hedouin S, et al. Designed inhibitors of insulin-degrading enzyme regulate the catabolism and activity of insulin. PLoS One 2010; 5(5): e10504.
36. Shakil S, Khan R, Tabrez S, et al. Interaction of human brain acetylcholinesterase with cyclophosphamide: a molecular modeling and docking study. CNS Neurol Disord Drug Targets 2011; 10(7): 845-8.
37. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci 2003; 4(2): 131-8.
38. Aisen PS, Cummings J, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2(3): a006395.
39. Onor ML, Trevisiol M, Aguglia E. Rivastigmine in the treatment of Alzheimer's disease: an update. Clin Interv Aging 2007; 2(1): 17-32.
40. Cummings JL. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003; 11(2): 131-45.
41. Ali R, Sheikh I, Jabir NR, Kamal, MA. Comparative Review of Decade's Research on Cholinesterase Inhibition. American Journal of Neuroprotection and Neuroregeneration 2012; 4(2): 136-44.
42. Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh, S. Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res 2005; 2(3): 307-18.
43. Mehta M, Adem A, Sabbagh M. New acetylcholinesterase inhibitors for Alzheimer's disease. Int J Alzheimers Dis 2012; 2012: 728983.
44. Wang BS, Wang H, Wei ZH, et al. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. Journal of Neural Transmission (Vienna: Austria: 1996) 2009; 116(4): 457-65.
45. Seidl C, Correia BL, Stinghen AEM, Santos, CAM. Acetylcholinesterase inhibitory activity of uleine from Himatanthus lancifolius. Zeitschrift für Naturforschung C 2010; 65(7-8): 440-4.
46. Guo AJY, Xie HQ, Choi RCY, et al. Galangin, a flavonol derived from Rhizoma Alpiniae Officinarum, inhibits acetylcholinesterase activity in vitro. Chem Biol Interact 2010; 187(1/3): 246-8.
47. de Paula AAN, Martins JBL, dos Santos ML, et al. New potential AChE inhibitor candidates. Eur J Med Chem 2009; 44(9): 3754-9.
48. Greig NH, Utsuki T, Ingram DK, et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci USA 2005; 102(47): 17213-8.
49. Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriar 2002; 14(Suppl 1): 77-91.
50. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978; 4(4): 273-7.
51. Omu AE, Al-Azemi MK, Omu FE, et al. Butyrylcholinesterase activity in women with diabetes mellitus in pregnancy: correlation with antioxidant activity. J Obstetr Gynaecol 2010; 30(2): 122-6.
52. Wagman AS, Johnson KW, Bussiere DE. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des 2004; 10(10): 1105-37.
53. Gao C, Hölscher C, Liu Y, Li L. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev Neurosci 2012; 23(1): 1-11.
54. Eldar-Finkelman H, Martinez A. GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Front Mol Neurosci 2011; 4: 32.
55. Martinez A, Gil C, Perez, DI. Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment. Int J Alzheimers Dis 2011; 2011: 280502.
56. Alonso D, Martínez A. In Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors. Anartinez Castro A, Medina M, Eds.; John Wiley & Sons, Inc 2006; pp. 307-31.
57. Hamann M, Alonso D, Martín-Aparicio E, et al. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. J Nat Prod 2007; 70(9): 1397-405.
58. Kramer T, Schmidt B, Lo Monte F. Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models. Int J Alzheimers Dis 2012; 2012: 381029.
59. Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286(5440): 735-41.
60. Li R, Lindholm K, Yang LB, et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA 2004; 101(10): 3632-7.
61. Meakin PJ, Harper AJ, Hamilton DL, et al. Reduction in BACE1 decreases body weight, protects against diet-induced obesity and enhances insulin sensitivity in mice. Biochem J 2012; 441(1): 285-96.
62. Ho L, Qin W, Pompl PN, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 2004; 18(7): 902-4.
63. Mattsson N, Rajendran L, Zetterberg H, et al. BACE1 inhibition induces a specific cerebrospinal fluid β -amyloid pattern that identifies drug effects in the central nervous system. PLoS ONE 2012; 7(2): e31084.
64. Craft S, Peskind E, Schwartz MW, et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998; 50(1): 164-8.
65. May PC, Dean RA, Lowe SL, et al. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β - secretase inhibitor. J Neurosci 2011; 31(46): 16507-16.
66. Ferretti MT, Allard S, Partridge V, Ducatenzeiler A, Cuello AC. Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology. J Neuroinflammation 2012; 9: 62.
67. Meakin P, Hamilton L, Jalicy S, Ashford M. Proceeding of Physiological Society. Proc Physiol Soc 2012; 27: PC153.
68. Cordes CM, Bennett RG, Siford GL, Hamel FG. Nitric oxide inhibits insulin-degrading enzyme activity and function through S-nitrosylation. Biochem Pharmacol 2009; 77(6): 1064-73.
69. Kuo W, Montag A, Rosner, M. Insulin-degrading enzyme is differentially expressed and developmentally regulated in various rat tissues. Endocrinology 1993; 132: 604-11.
70. Zhao L, Teter B, Morihara T, et al. Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 2004; 24(49): 11120-6.
71. Cordes CM, Bennett RG, Siford GL, Hamel FG. Redox regulation of insulin degradation by insulin-degrading enzyme. PLoS ONE 2011; 6(3): e18138.
72. Fakhrai-Rad H, Nikoshkov A, Kamel A, et al. Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats. Hum Mol Genet 2000; 9(14): 2149-58.
73. Hamel FG, Upward JL, Bennett RG. In vitro inhibition of insulindegrading enzyme by long-chain fatty acids and their coenzyme A thioesters. Endocrinology 2003; 144(6): 2404-8.
74. Frenkel D, Kopelevich A, Lifshitz V, Benromano T, Borenstein N. Peptides, pharmaceutical compositions comprising same and uses thereof. 2010; WO 2010086867 A3.
75. Apostolatos A, Cooper D, Patel N. Insulin improves memory and cognition via protein kinase c delta. Endocr Abstr 2012; 29: p1106.
76. Duarte AI, Moreira PI, Oliveira CR. Insulin in central nervous system: more than just a peripheral hormone. J Aging Res 2012; 2012: 384017.
77. Reger MA, Watson GS, Frey WH 2nd, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 2006; 27(3): 451-8.
78. Tundo GR, Sbardella D, Ciaccio C, et al. Insulin-degrading Enzyme (IDE): A novel heat shock-like protein. J Biol Chem 2013; 288(4): 2281-9.
79. Cui J, Zhang M, Zhang YQ, Xu ZH. JNK pathway: diseases and therapeutic potential. Acta Pharmacol Sin 2007; 28(5): 601-8.
80. Shoji M, Iwakami N, Takeuchi S, et al. JNK activation is associated with intracellular beta-amyloid accumulation. Brain Res Mol Brain Res 2000; 85(1-2): 221-33.
81. Wei W, Norton DD, Wang X, Kusiak, JW. A beta 17-42 in Alzheimer's disease activates JNK and caspase-8 leading to neuronal apoptosis. Brain 2002; 125(Pt 9): 2036-43.
82. Tare M, Modi RM, Nainaparampil JJ, et al. Activation of JNK signaling mediates amyloid-ß-dependent cell death. PLoS ONE 2011; 6(9): e24361.
83. Kaneto H, Matsuoka TA, Katakami N, et al. Oxidative stress and the JNK pathway are involved in the development of type 1 and type 2 diabetes. Curr Mol Med 2007; 7(7): 674-86.
84. Beeler N, Riederer BM, Waeber G, Abderrahmani A. Role of the JNK-interacting protein 1/islet brain 1 in cell degeneration in Alzheimer disease and diabetes. Brain Res Bull 2009; 80(4/5): 274-81.